Second series C tranche brings in £4m for fungal test co:
This article was originally published in Clinica
University of Manchester spin-out Myconostica has raised £3.9m ($7.8m) in the second tranche of its series C financing, bringing the total investment in that round to £4.4m. The financing was led by Amphion, which owns 25% of Myconostica, and included the participation of Nexus Medical Partners, Innoven Partenaires and other UK and international investors.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.